Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

Fig. 1

SRPK1 is expressed in more than half of ENKTL patients and is associated with adverse clinical outcomes. A Immunohistochemical expression of SRPK1 in NK/T-cell lymphomas. B Distribution of SRPK1 expression for different IHC scores. C Relative SRPK1 mRNA expression levels in ENKTL patients. D and E Kaplan‒Meier survival analysis revealed that SRPK1 expression was significantly associated with a shorter OS and PFS

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us